Inflammation in end-stage renal disease: Sources, consequences, and therapy

被引:326
作者
Stenvinkel, P [1 ]
Alvestrand, A [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Renal Med K56, S-14186 Stockholm, Sweden
关键词
D O I
10.1046/j.1525-139X.2002.00083.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) remains the main cause of morbidity and mortality in patients with end-stage renal disease (ESRD). Although traditional risk factors are common in ESRD patients, they alone may not be sufficient to account for the high prevalence of CVD in this condition. Recent evidence demonstrates that chronic inflammation, a nontraditional risk factor which is commonly observed in ESRD patients, may cause malnutrition and progressive atherosclerotic CVD by several pathogenetic mechanisms. The causes of inflammation in ESRD are multifactorial and, while it may reflect underlying CVD, an acute-phase reaction may also be a direct cause of vascular injury by several pathogenetic mechanisms. Available data suggest that proinflammatory cytokines play a central role in the genesis of both malnutrition and CVD in ESRD. Thus it could be speculated that suppression of the vicious cycle of malnutrition, inflammation, and atherosclerosis (MIA syndrome) would improve survival in dialysis patients. Recent evidence has demonstrated strong associations between inflammation and both increased oxidative stress and endothelial dysfunction in ESRD patients. As there is not yet any recognized, or even proposed, treatment for ESRD patients with chronic inflammation, it would be of obvious interest to study the long-term effect of various anti-inflammatory treatment strategies on the nutritional and cardiovascular status as well as outcome in these patients.
引用
收藏
页码:329 / 337
页数:9
相关论文
共 110 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]  
Alvestrand A, 1997, KIDNEY INT, V52, pS48
[3]  
Avram M M, 1996, Perit Dial Int, V16 Suppl 1, pS190
[4]  
Ayus JC, 1998, J AM SOC NEPHROL, V9, P1314
[5]  
BEMELMANS MHA, 1993, J IMMUNOL, V150, P2007
[6]   Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo [J].
Bhagat, K ;
Vallance, P .
CIRCULATION, 1997, 96 (09) :3042-3047
[7]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[8]   Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients [J].
Bologa, RM ;
Levine, DM ;
Parker, TS ;
Cheigh, JS ;
Serur, D ;
Stenzel, KH ;
Rubin, AL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :107-114
[9]   Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines [J].
Bolton, CH ;
Downs, LG ;
Victory, JGG ;
Dwight, JF ;
Tomson, CRV ;
Mackness, MI ;
Pinkney, JH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (06) :1189-1197
[10]   PLASMA TUMOR-NECROSIS-FACTOR SOLUBLE RECEPTORS IN CHRONIC-RENAL-FAILURE [J].
BROCKHAUS, M ;
BARKHAYIM, Y ;
GURWICZ, S ;
FRENSDORFF, A ;
HARAN, N .
KIDNEY INTERNATIONAL, 1992, 42 (03) :663-667